Top

Lung

Published in:

07-02-2023 | Bronchiectasis | BRONCHIECTASIS

Tiotropium in Patients with Bronchiectasis: A Prospective Cohort Study

Authors: Zu-Liang Shi, Hong-Ying Zhang, Hai-Bo Peng, Zhong-Ming Zhu

Published in: Lung | Issue 1/2023

Abstract

Purpose

There are limited studies on the use of bronchodilators for the treatment of bronchiectasis. This study investigated the efficacy of tiotropium in patients with bronchiectasis and airflow limitation.

Methods

This study was a prospective cohort study, including 169 patients with bronchiectasis and airflow limitation from 2015 to 2019. The clinical outcomes observed in our study were the effect of tiotropium on the frequency of moderate exacerbations, the time to the first severe exacerbation, and the annual decline in FEV₁.

Results

After 12 months, the annual decline in the FEV₁ after bronchodilator use was 27.08 ml or 42.9 ml per year in the group with or without tiotropium, respectively. Treatment with tiotropium was associated with a decreased risk of moderate exacerbation of bronchiectasis (Adjusted RR 0.618 95% CI 0.493–0.774; P < 0.005). The time to the first severe acute exacerbation of bronchiectasis in the tiotropium group was longer than the non-tiotropium group (Adjusted HR 0.333 95% CI 0.219–0.506; P < 0.001).

Conclusion

In conclusion, prospective cohort study showed that tiotropium effectively ameliorated the annual decline in the FEV_1, with a lower-risk rate of moderate exacerbations and prolonging the time to the first-time severe exacerbation in patients with bronchiectasis and airflow limitation.

Polverino E, Goeminne PC, McDonnell MJ et al (2017) European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J 50(3):1700629. https://doi.org/10.1183/13993003.00629-2017CrossRefPubMed

Cole PJ (1986) Inflammation: a two-edged sword–the model of bronchiectasis. Eur J Respir Dis Suppl 147:6–15PubMed

Guan WJ, Yuan JJ, Gao YH et al (2016) Impulse oscillometry and spirometry small airway parameters in mild to moderate bronchiectasis. Respir Care 61(11):1513–1522. https://doi.org/10.4187/respcare.04710CrossRefPubMed

Guan WJ, Yuan JJ, Huang Y, Li HM, Chen RC, Zhong NS (2017) Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis. PLoS One 12(9):e0183779. https://doi.org/10.1371/journal.pone.0183779CrossRefPubMedPubMedCentral

Jeong HJ, Lee H, Carriere KC, Kim JH, Han JH, Shin B, Jeong BH, Koh WJ, Kwon OJ, Park HY (2016) Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int J Chron Obstruct Pulmon Dis 7(11):2757–2764. https://doi.org/10.2147/COPD.S115581CrossRef

Lee SY, Lee JS, Lee SW, Oh YM (2021) Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. J Thorac Dis 13(1):169–177. https://doi.org/10.21037/jtd-20-1282CrossRefPubMedPubMedCentral

Martínez-García MÁ, Oscullo G, García-Ortega A, Matera MG, Rogliani P, Cazzola M (2022) Rationale and clinical use of bronchodilators in adults with bronchiectasis. Drugs 82(1):1–13. https://doi.org/10.1007/s40265-021-01646-3CrossRefPubMed

Hill AT et al (2019) British thoracic society guideline for bronchiectasis in adults. Thorax 74(Suppl1):169. https://doi.org/10.1136/thoraxjnl2018212463CrossRef

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR et al (2017) European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J 50(3):1700629. https://doi.org/10.1183/13993003.00629-2017CrossRefPubMed

10.

Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M et al (2018) Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol (Engl Ed) 54(2):88–98. https://doi.org/10.1016/j.arbres.2017.07.016CrossRefPubMed

11.

Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26(2):319–338. https://doi.org/10.1183/09031936.05.00034805CrossRefPubMed

12.

Tsikrika S, Dimakou K, Papaioannou AI et al (2017) The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 99:281–286. https://doi.org/10.1016/j.cyto.2017.08.005CrossRefPubMed

13.

Clofent D, Álvarez A, Traversi L, Culebras M, Loor K, Polverino E (2021) Comorbidities and mortality risk factors for patients with bronchiectasis. Expert Rev Respir Med 15(5):623–634. https://doi.org/10.1080/17476348.2021.1886084CrossRefPubMed

14.

Radovanovic D, Santus P, Blasi F, Sotgiu G, D’Arcangelo F, Simonetta E, Contarini M, Franceschi E, Goeminne PC, Chalmers JD, Aliberti S (2018) A comprehensive approach to lung function in bronchiectasis. Respir Med 145:120–129. https://doi.org/10.1016/j.rmed.2018.10.031CrossRefPubMed

15.

White AJ, O’Brien C, Hill SL, Stockley RA (2005) Exacerbations of COPD diagnosed in primary care: changes in spirometry and relationship to symptoms. COPD 2(4):419–425. https://doi.org/10.1080/15412550500346477CrossRefPubMed

16.

Guan W-j, Gao Y-h, Xu G, Lin Z-y, Tang Y et al (2014) Characterization of lung function impairment in adults with bronchiectasis. PLoS ONE 9(11):e113373. https://doi.org/10.1371/journal.pone.0113373CrossRefPubMedPubMedCentral

17.

Håkansson KEJ, Fjaellegaard K, Browatzki A, Dönmez Sin M, Ulrik CS (2021) Inhaled corticosteroid therapy in bronchiectasis is associated with all-cause mortality: a prospective cohort study. Int J Chron Obstruct Pulmon Dis 16(16):2119–2127. https://doi.org/10.2147/COPD.S311236CrossRefPubMedPubMedCentral

18.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364(12):1093–1103. https://doi.org/10.1056/NEJMoa1008378CrossRefPubMed

19.

Martinez-Garcia MA, Polverino E, Aksamit T (2018) Bronchiectasis and chronic airway disease: it is not just about asthma and COPD. Chest 154(4):737–739. https://doi.org/10.1016/j.chest.2018.02.024CrossRefPubMed

20.

Lonni S, Chalmers JD, Goeminne PC et al (2015) Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 12:1764–1770. https://doi.org/10.1513/AnnalsATS.201507-472OCCrossRefPubMedPubMedCentral

21.

Jayaram L, Vandal AC, Chang CL, Lewis C, Tong C, Tuffery C, Bell J, Fergusson W, Jeon G, Milne D, Jones S, Karalus N, Hotu S, Wong C (2022) Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J 59(6):2102184. https://doi.org/10.1183/13993003.02184-2021CrossRefPubMedPubMedCentral

22.

Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M et al (2007) Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132:1565–1572. https://doi.org/10.1378/chest.07-0490CrossRefPubMed

23.

Ma Y, Niu Y, Tian G, Wei J, Gao Z (2015) Pulmonary function abnormalities in adult patients with acute exacerbation of bronchiectasis: a retrospective risk factor analysis. Chron Respir Dis 12(3):222–229. https://doi.org/10.1177/1479972315583042CrossRefPubMed

24.

Wang H, Ji XB, Mao B et al (2018) Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. BMJ Open 8(3):e014613. https://doi.org/10.1136/bmjopen-2016-014613CrossRefPubMedPubMedCentral

Title: Tiotropium in Patients with Bronchiectasis: A Prospective Cohort Study
Authors: Zu-Liang Shi
Hong-Ying Zhang
Hai-Bo Peng
Zhong-Ming Zhu
Publication date: 07-02-2023
Publisher: Springer US
Keywords: Bronchiectasis
Dyspnea
Tiotropium
Dyspnea
Published in: Lung / Issue 1/2023
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-023-00597-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Sesamin Induces the Transdifferentiation of Type II Alveolar Epithelial Cells via AnnexinA1 and TRPV1

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

LUNG Year in Review: 2022

Bronchodilators in bronchiectasis: we urgently need more trials

Healthcare-Seeking Behaviour Due to Cough in Finnish Elderly: Too Much and Too Little

PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials